How should ESBL-producing organisms be treated according to the guidelines?

• A. Penicillin
• B. Cefoxitin
• C. Carbapenems, never penicillin or 3rd generation cephalosporins
• D. Doxycycline

Answer: (C)

ESBL enzymes break down many beta-lactam antibiotics, including penicillins and third-generation cephalosporins, making those drugs unreliable for infections caused by ESBL-producing organisms. Because these pathogens inactivate those antibiotics, treatment must use an agent that remains active in the face of ESBLs. Carbapenems fit that need well—they’re stable to ESBL hydrolysis and have strong activity against many ESBL-producing gram-negative bacteria, making them the recommended option for invasive infections. Doxycycline isn’t consistently effective against ESBL producers, and cefoxitin, though a cephamycin, isn’t reliably sufficient for severe ESBL infections. In short, guidelines favor carbapenems for serious ESBL-associated infections because other beta-lactams are inactivated by the enzymes.